Gene-modified T cell therapy for refractory acute myeloid leukemia harboring a FLT3/ITD mutation
| Project/Area Number |
26461574
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Pediatrics
|
|---|
| Research Institution | Shinshu University |
|---|
Principal Investigator |
NAKAZAWA Yozo 信州大学, 学術研究院医学系, 教授 (60397312)
|
|---|
| Project Period (FY) |
2014-04-01 – 2017-03-31
|
| Project Status |
Completed (Fiscal Year 2016)
|
| Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2016: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2015: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2014: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Keywords | キメラ抗原受容体 / T細胞療法 / がん免疫療法 / 急性骨髄性白血病 / CAR-T療法 / Flt3/ITD / Flt3 / FLT3/ITD |
|---|
| Outline of Final Research Achievements |
Patients with FLT3/ITD-mutated acute myeloid leukemia (AML) have a poor prognosis. A FLT3/ITD-mutated AML cell line, MV4-11, highly express GM-CSF receptors (GMR). We developed T cells engineered to express a chimeric antigen receptor (CAR) targeting the GMR. GMR CAR T cells eliminated MV4-11 cells up to 98% after a 5 days-coculture at a T cells: leukemia cells ratio of 1:5. Adoptive immunotherapy using GMR CAR T cells may a promising option for AML harboring a FLT3/ITD mutation.
|
Report
(4 results)
Research Products
(15 results)
-
-
-
-
-
[Journal Article] Anti-leukemic potency of piggyBac-mediated CD19-specific T cells against refractory Philadelphia chromosome-positive acute lymphoblastic leukemia.2014
Author(s)
Saito S, Nakazawa Y, Sueki A, Matsuda K, Tanaka M, Yanagisawa R, Maeda Y, Sato Y, Okabe S, Inukai T, Sugita K, Wilson MH, Rooney CM, Koike K.
-
Journal Title
Cytotherapy
Volume: 16
Issue: 9
Pages: 1257-1269
DOI
Related Report
Peer Reviewed / Open Access
-
-
-
-
-
-
-
-
-
-
